LTL-237 datasheet

Origin	Primary human ovarian cancer	**Histopathology**	Serous adenocarcinoma
Year of establishment	2006	**Doubling time**	20.35 days (sub-renal)
Local invasion	Yes	**Metastasis**	Yes (distant organs)
Drug sensitivity	carboplatin 80 mg/kg + paclitaxol 24mg/kg (T/C = 18.77%, response)		

The LTL-237 was developed from a patient's primary ovarian cancer (high-grade (grade 3/3) serous papillary cystic adenocarcinoma). Histopathologically, it closely resembles the patient's tumor (Figs 1, 2). When grafted under the renal capsules of SCID mice, the LTL-237 shows local invasion into adjacent host kidney parenchyma and metastasis to distant organs. The LTL-237 has peritoneal cavity spreading ability and produce bloody ascites. The LTL-237 also grows well subcutaneously.



Fig. 1. H&E stained LTL-237 tissue sections.

The LTL-237 is a serous adenocarcinoma, retaining maior characteristics of the original patient's cancer. The tumor cells form fine papillae locally. Giant cells with large bizarre nuclei are frequently seen (arrows). (x400)



Fig. 2. Patient's cancer tissue before grafting.

Major characteristics: fine papillae and giant cells with large, bizarre nuclei (arrows). (x400)



Fig. 3. LTL-237 Lung metastases in SCID mice. (x400)

Genetic and epigenetic characteristics

BRCA wild type

Tumor line tissue (in Tissue Microarrays) for IHC and ISH is in place for screening potential targets upon request.

Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis and angiogenesis.

2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity. (No response to Sunitinib, an angiogenesis inhibitor)

3. Study of mechanisms underlying tumor growth, progression and metastasis.

References

1. Lee et al., Gynecologic Oncology 2005; 96: 48-55

2. Press et al., Gynecologic Oncology 2008; 110: 256-264

For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013